

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---------------------------------------------------------------------------------------------------------------------------------------|------|--------------------------|--------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/599,550 |
| | | Filing Date | September 29, 2006 |
| | | First Named Inventor | OKABE, Hidetoshi |
| | | Art Unit | N/A |
| | | Examiner Name | N/A |
| Sheet 1 | of 1 | Attorney Docket Number | 20080-00008 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /M.N./ | C1 | PRICE-SCHIAVI et al., "RAT MUC4 (SIALOMUCIN COMPLEX) REDUCES BINDING OF ANTI-ERBB2 ANTIBODIES TO TUMOR CELL SURFACES, A POTENTIAL MECHANISM FOR HERCEPTIN RESISTANT," Int. J. Cancer, 99:783-791 (2002). | |
| | C2 | BARTLETT et al., "The clinical evaluation of HER-2 status: which test to use?" Journal of Pathology, 199:411-417 (2003) | |
| | C3 | RAMSAUER et al., "Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, Translocates ErbB2 to the Apical Surface in Polarized Epithelial Cells," Journal of Biological Chemistry, 278(32): 30142-30147 (2003). | |
| | C4 | SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," Science, 235: 177-182 (1987). | |
| | C5 | HYNES and STERN, "The biology of erbB-2/neu/HER-2 and its role in cancer," Biochimica et Biophysica Acta, 1198: 165-184 (1994). | |
| ↓ | C6 | DOUGALL et al., "The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies," Oncogene, 9: 2109-2123 (1994). | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Meera Natarajan/ | Date Considered | 08/29/2007 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | |
|---------------------------------------------------------------------------------------------------------------------------------------|------|--------------------------|--------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | |
| | | Application Number | 10/599,550 |
| | | Filing Date | September 29, 2006 |
| | | First Named Inventor | OKABE, Hidetoshi |
| | | Art Unit | N/A |
| | | Examiner Name | N/A |
| Sheet 1 | of 1 | Attorney Docket Number | 20080-00008 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /M.N./ | C1 | PRICE-SCHIAVI et al., "RAT MUC4 (SIALOMUCIN COMPLEX) REDUCES BINDING OF ANTI-ERBB2 ANTIBODIES TO TUMOR CELL SURFACES, A POTENTIAL MECHANISM FOR HERCEPTIN RESISTANT," Int. J. Cancer, 99:783-791 (2002). | |
| /M.N./ | C2 | BARTLETT et al., "The clinical evaluation of HER-2 status: which test to use?" Journal of Pathology, 199:411-417 (2003) | |
| /M.N./ | C3 | RAMSAUER et al., "Muc4/Sialomucin Complex, the Intramembrane ErbB2 Ligand, Translocates ErbB2 to the Apical Surface in Polarized Epithelial Cells," Journal of Biological Chemistry, 278(32): 30142-30147 (2003). | |
| /M.N./ | C4 | SLAMON et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene," Science, 235: 177-182 (1987). | |
| /M.N./ | C5 | HYNES and STERN, "The biology of erbB-2/neu/HER-2 and its role in cancer," Biochimica et Biophysica Acta, 1198: 165-184 (1994). | |
| /M.N./ | C6 | DOUGALL et al., "The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies," Oncogene, 9: 2109-2123 (1994). | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|-------------------|-----------------|------------|
| Examiner Signature | /Meera Natarajan/ | Date Considered | 08/29/2007 |
|--------------------|-------------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.